Fate Therapeutics Inc
$ 2.57
-6.20%
02 Jun - close price
- Market Cap 319,372,000 USD
- Current Price $ 2.57
- High / Low $ 2.77 / 2.55
- Stock P/E N/A
- Book Value 1.55
- EPS -1.09
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -0.56 %
- 52 Week High 2.88
- 52 Week Low 0.91
About
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.
Analyst Target Price
$5.41
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-02-26 | 2025-11-13 | 2025-08-12 | 2025-05-13 | 2025-03-05 | 2024-11-12 | 2024-08-13 | 2024-05-09 | 2024-02-26 | 2023-11-08 | 2023-08-08 |
| Reported EPS | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 | -0.44 | -0.4 | -0.33 | -0.47 | -0.45 | -0.46 | -0.54 |
| Estimated EPS | -0.28 | -0.274 | -0.28 | -0.34 | -0.38 | -0.4238 | -0.41 | -0.45 | -0.45 | -0.52 | -0.56 | -0.58 |
| Surprise | 0.02 | 0.004 | 0.01 | 0.05 | 0.06 | -0.0162 | 0.01 | 0.12 | -0.02 | 0.07 | 0.1 | 0.04 |
| Surprise Percentage | 7.1429% | 1.4599% | 3.5714% | 14.7059% | 15.7895% | -3.8226% | 2.439% | 26.6667% | -4.4444% | 13.4615% | 17.8571% | 6.8966% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.26 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FATE
2026-06-01 12:10:36
Fate Therapeutics presented promising Phase 1 clinical data for its off-the-shelf CAR T-cell program FT836 at the ASCO Annual Meeting. The data showed meaningful tumor reduction in metastatic colorectal cancer patients without conditioning chemotherapy, demonstrating favorable safety and evidence of FT836 trafficking to and persisting within tumor tissue. This novel 9-point edited CAR T-cell product incorporates Sword and Shield™ technology, which is designed to eliminate the need for lymphodepleting conditioning chemotherapy and enable broad patient access.
2026-05-29 13:39:17
This article from Quantisnow highlights a biopharmaceutical company, implied to be Artiva Biotherapeutics, that is valued at $13 million and focuses on utilizing the immune system to target cancer. It mentions several related companies in the healthcare sector and provides context on Quantisnow's role in delivering real-time market data and news to retail investors. The piece also includes snippets of recent financial activities and news pertaining to these companies.
2026-05-22 05:30:00
Fate Therapeutics announced upcoming presentations at the 2026 ASCO and EULAR annual meetings, showcasing data from its off-the-shelf CAR T-cell therapy pipeline. The presentations will highlight clinical trial results for product candidates like FT836 for solid tumors and FT819 for autoimmune diseases, including Systemic Lupus Erythematosus (SLE), as well as a dual-CAR T-cell therapy, FT839, for autoimmune conditions. These presentations underscore the company's progress in developing iPSC-derived cellular immunotherapies for oncology and autoimmune disorders.
2026-05-21 19:39:38
Fate Therapeutics President and CEO Bahram Valamehr sold 28,946 shares of common stock at a weighted average price of $1.8822 per share. This automatic sale on May 20, 2026, was conducted to cover tax withholding obligations related to the vesting of 50,000 performance-based RSUs granted in July 2024. Following this transaction, Valamehr directly holds 635,762 shares and the sale was not discretionary, but rather an irrevocable sell-to-cover election.
2026-05-21 19:39:38
Fate Therapeutics officer Cindy Tahl sold 25,590 shares of common stock at a weighted average price of $1.879 per share. This was a pre-arranged, non-discretionary "sell-to-cover" transaction to meet tax withholding obligations arising from the vesting of 50,000 performance-based RSUs. Following this sale, Tahl directly holds 628,155 shares of Fate Therapeutics common stock.
2026-05-21 18:39:46
Fate Therapeutics announced presentations at the 2026 ASCO and EULAR Annual Meetings, highlighting data from its off-the-shelf CAR T-cell programs. The presentations will feature preliminary Phase 1 results for FT836 targeting solid tumors at ASCO, and safety and efficacy data for FT819 in SLE, along with details on FT839 for autoimmune diseases, at EULAR. These presentations underscore the company's progress in developing iPSC-derived cellular immunotherapies for cancer and autoimmune conditions.
